Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01168050
Other study ID # P081237
Secondary ID
Status Recruiting
Phase Phase 2
First received July 21, 2010
Last updated February 7, 2011
Start date July 2010
Est. completion date December 2013

Study information

Verified date February 2011
Source Assistance Publique - Hôpitaux de Paris
Contact Zakia Idir, PhD
Phone +33 1 4484 1747
Email zakia.idir@sls.aphp.fr
Is FDA regulated No
Health authority France: Ministry of Health
Study type Interventional

Clinical Trial Summary

NILOMEL is a phase II multicentric uncontrolled open national trial assessing the efficacy of Nilotinib in first or second line treatment of primary melanomas , stage III unresectable melanomas, or Stage IV melanomas with c-KIT mutation or amplification. The primary objective is overall response rate (partial and complete response) according to RECIST 1.1 criteria, assessed using CT-SCAN (stage IV melanoma) or MRI (unresectable melanoma) after 6 months therapy with Nilotinib 800 mg/d. Secondary objectives include:

- Disease control rate (complete, partial response and stable disease)

- Metabolic response

- Tolerance NCI CTCAE Version 3.0

- Biomarkers associated to response and disease control.


Description:

NILOMEL is a phase II multicentric uncontrolled open national trial assessing the efficacy of Nilotinib in first or second line treatment of primary melanomas , stage III unresectable melanomas, or Stage IV melanomas with c-KIT mutation or amplification (in case of c-KIT amplification, no B-RAF nor N-Ras mutation should be detected). The primary objective is overall response rate (partial and complete response) according to RECIST 1.1 criteria, assessed using CT-SCAN (stage IV melanoma) or MRI (unresectable melanoma) after 6 months therapy with Nilotinib 800 mg/d. Secondary objectives include:

- Disease control rate (complete, partial response and stable disease) according to RECIST

- Metabolic response rate (TEP-SCAN)

- Tolerance NCI CTCAE Version 3.0

- Biomarkers associated to response and disease control (evaluated at M0, M1 and M6). Protein analysis of c-KIT, PI3K, MAPK and STAT signalling pathways as well as PDGFR and Ephrin signalling pathways.

Patients with progressive disease after 3 months therapy will be withdrawn. Patient with stable disease after 3 months will continue Nilotinib until evaluation at 6 months. Patients with stable disease or progressive disease at 6 months will continue Nilotinib until progression.

The trial has been planned using a one-stage design (Fleming TR) . We considered that a response rate under 7.5% would define the null hypothesis of no efficacy . To detect a response rate of 30% or more with power 90% using a one-sided test at the 0.05 level, 25 patients have to be recruited.

Accrual for 2.5 years total study duration: 3 years


Recruitment information / eligibility

Status Recruiting
Enrollment 25
Est. completion date December 2013
Est. primary completion date December 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients with histologically proven melanoma with either c-KIT mutation or C-KIT amplification (without BRAF or NRAS mutation)

- Unresectable primary or stage III or stage IV melanoma

- Measurable disease (RECIST)

- The inclusion of patients with primary tumor or metastasis accessible to sequential biopsies will be favored. If such lesions are present, biopsies are mandatory and not optional

- No more than 1 previous specific therapy excluding tyrosine kinase inhibitors. 4 weeks wash out will be needed after cytotoxic therapy , 12 weeks wash out after anti -CTLA4 therapy or any immunological treatment

- No radiotherapy within 4 weeks ; previously irradiated lesion will not be considered as measurable unless progression at inclusion

- ECOG performance status < 2

- WBC = 3,000/mm³

- PNN = 1,500/mm³ (G-CSF allowed)

- platelets = 100,000/mm³

- Hb = 9.0 g/dL ( transfusions allowed as well as recombinant erythropoetin)

- Creatinin clearance > 40ml/mn

- Normal kalemia

- Normal magnesemia

- Total bilirubin <1.5N ; ASAT and ALAT <2.5N

- PT/INR and PTT normal

- NYHA class < 3

- Signed Written Informed Consent

- Affiliated to the National Health Insurance

Exclusion Criteria:

- Patients refusal

- Age < 18 years

- Fertile women who do not want or cannot use effective contraception during the study and up to 8 weeks after the end of study

- Women pregnant or nursing

- Women with positive pregnancy test at inclusion or before treatment initiation

- Fertile and sexually active men whose partner are fertile women who do not use effective contraception

- Clinical and/or radiographic evidence of active cerebral metastases

- Severe evolutive infection

- Known HIV infection

- Concomitant therapy with any other anti-cancer, immunomodulator or immunosuppressing agent or radiotherapy (except palliative care if bone metastases, after acceptance of principal investigator).

- Previous use of tyrosine kinase inhibitors

- More than one line of prior systemic therapies of melanoma by anti-cancer agent or immunotherapy.

- Received experimental treatment within 4 weeks of inclusion

- Pace-maker

- Cardiac dysfunction, as evaluated by one of:

- Ejection fraction < 45% (less than 28 days from inclusion)

- Congenital prolonged QT

- QTc > 450 ms

- Ventricular tachyarrhythmia within the past 6 months

- Bradycardia at rest < 50/mn

- Major conduction dysfunction

- Myocardial infarction within the previous 6 months

- Unstable angina

- Uncontrolled hypertension

- Digestive disease that may inhibited NILITINIB absorption

- Concomitant medication that may increase QT

- Taking CYP3A4 inhibitors

- Eating Sevilla oranges (or Sevilla oranges derivates), grapefruit (or grapefruit juice), grapes (or grapes juice), pomegranate (or pomegranate juice)

- Hereditary galactose intolerance, Lapp-lactase deficiency or glucose-galactose malabsorption.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Nilotinib
Nilotinib 400 mg twice per day

Locations

Country Name City State
France Hôpital Saint-Louis Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective response Partial or complete response per Response Evaluation Criteria in Solid Tumors (RECIST). 6 months No
Secondary Disease control Complete or partial response or stable disease per Response Evaluation Criteria in Solid Tumors (RECIST). 6 months No
Secondary Objective response Partial or complete response per Response Evaluation Criteria in Solid Tumors (RECIST). 3 months No
Secondary Metabolic response Metabolic response as evaluated by TEP-SCAN 6 months No
Secondary Tolerance Tolerance will be evaluated according to National Cancer Institute (NCI) Criteria for Adverse Events, CTCAE v3.0 1 year Yes
See also
  Status Clinical Trial Phase
Completed NCT02107755 - Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma Phase 2
Withdrawn NCT01216787 - RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery Phase 2
Active, not recruiting NCT01026324 - Dinaciclib in Treating Patients With Stage III-IV Melanoma Phase 1/Phase 2
Completed NCT01010984 - LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma N/A
Completed NCT00553306 - Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma Phase 1/Phase 2
Completed NCT00121225 - Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma Phase 2
Completed NCT00019448 - Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma Phase 2
Active, not recruiting NCT03200847 - Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma Phase 1/Phase 2
Active, not recruiting NCT03235245 - Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib Phase 2
Terminated NCT01875653 - Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma Phase 3
Completed NCT01748747 - Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery Early Phase 1
Terminated NCT01316692 - Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma Phase 2
Active, not recruiting NCT01120275 - Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma Phase 2
Terminated NCT01026051 - Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma Phase 2
Terminated NCT01217411 - RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer Phase 1
Terminated NCT01166126 - Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV Phase 2
Completed NCT01037790 - Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer Phase 2
Completed NCT00288041 - Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma Phase 2
Completed NCT00072163 - Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma Phase 2
Completed NCT00074308 - Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers Phase 1/Phase 2